News stories about Fresenius Medical Care Corporation (NYSE:FMS) have been trending somewhat positive this week, Accern reports. Accern ranks the sentiment of press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Fresenius Medical Care Corporation earned a media sentiment score of 0.20 on Accern’s scale. Accern also assigned news stories about the company an impact score of 46.0631525893961 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Here are some of the news stories that may have effected Accern Sentiment Analysis’s analysis:
- FTC seeks more information on Fresenius’ $2B NxStage buy (massdevice.com)
- Reviewing Fresenius Medical Care Corporation (FMS) & DaVita HealthCare Partners (DVA) (americanbankingnews.com)
- Fresenius Medical Care’s (FMS) Solid Earnings Visibility Keeps it a Buy (investorplace.com)
- Renal dialysis Market Comprehensive Analysis & is to Grow USD 26.6 billion till 2023 at a CAGR of 7.1% (abnewswire.com)
- Hemodialysis & Peritoneal Dialysis Market: 2017 Global Industry Trends, Growth, Share, Size and 2022 Forecast Report (medgadget.com)
A number of brokerages have issued reports on FMS. Zacks Investment Research lowered Fresenius Medical Care Corporation from a “hold” rating to a “sell” rating in a research note on Tuesday, October 3rd. Nord/LB reiterated a “buy” rating on shares of Fresenius Medical Care Corporation in a research report on Wednesday, June 28th. Royal Bank Of Canada reiterated a “hold” rating and set a $44.00 price objective on shares of Fresenius Medical Care Corporation in a research report on Wednesday, July 5th. UBS AG restated a “sell” rating on shares of Fresenius Medical Care Corporation in a report on Tuesday, July 4th. Finally, BidaskClub lowered Fresenius Medical Care Corporation from a “strong-buy” rating to a “buy” rating in a report on Monday, July 24th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $48.50.
Fresenius Medical Care Corporation (NYSE FMS) opened at 48.89 on Friday. Fresenius Medical Care Corporation has a 52-week low of $38.05 and a 52-week high of $50.22. The firm has a market capitalization of $30.00 billion, a P/E ratio of 20.98 and a beta of 0.48. The firm’s 50-day moving average is $48.46 and its 200 day moving average is $47.03.
Fresenius Medical Care Corporation (NYSE:FMS) last issued its quarterly earnings results on Tuesday, August 1st. The company reported $0.48 EPS for the quarter, missing the consensus estimate of $0.53 by ($0.05). Fresenius Medical Care Corporation had a return on equity of 11.57% and a net margin of 7.06%. The business had revenue of $4.47 billion for the quarter, compared to the consensus estimate of $5.20 billion. During the same period last year, the firm earned $0.96 earnings per share. The company’s quarterly revenue was up 11.1% compared to the same quarter last year. Equities analysts anticipate that Fresenius Medical Care Corporation will post $2.35 EPS for the current year.
About Fresenius Medical Care Corporation
Fresenius Medical Care AG & Co KGaA is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company’s segments include North America Segment, the Europe, Middle East and Africa (EMEA) Segment, the Asia-Pacific Segment and the Latin America Segment.
Receive News & Ratings for Fresenius Medical Care Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care Corporation and related companies with MarketBeat.com's FREE daily email newsletter.